
Jan 13 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE THERAPEUTICS PROVIDES CORPORATE UPDATES AND HIGHLIGHTS PRIORITIES FOR 2026
EDGEWISE THERAPEUTICS INC - ANTICIPATE PHASE 2 RESULTS FOR EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY (HCM) IN FIRST HALF OF 2026
EDGEWISE THERAPEUTICS INC - PREPARE FOR NDA SUBMISSION FOR SEVASEMTEN IN BECKER IN H1 2027
EDGEWISE THERAPEUTICS INC - TO INITIATE EDG-7500 PHASE 3 TRIAL IN INDIVIDUALS WITH OBSTRUCTIVE AND NONOBSTRUCTIVE HCM IN SECOND HALF OF 2026